Phillips Andrew John Buys Shares of MoonLake Immunotherapeutics

Phillips Andrew John recently bought 22,195 shares of MoonLake Immunotherapeutics, trading on the NasdaqCM under the ticker MLTX. This transaction took place on June 17, 2026, with shares trading at approximately $19.19 each.

MoonLake Immunotherapeutics Stock Snapshot

Shares of NasdaqCM:MLTX traded near $19.19. MoonLake Immunotherapeutics has a market cap of about $1.41 billion and a forward P/E ratio indicating it isn't profitable yet. The stock's beta is 1.036, suggesting it has slightly more volatility than the market. Over the past 52 weeks, the stock has ranged from $5.95 to $62.75, with a 50-day moving average of $17.88 and a 200-day moving average of $19.01. The company boasts a strong current ratio of 8.601 and a quick ratio of 7.887, but it carries a debt-to-equity ratio of 39.682.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biotechnology company based in Zug, Switzerland. It focuses on developing therapies for inflammatory skin and joint diseases. The company's leading product is Sonelokimab, a novel treatment targeting IL-17A and IL-17F for conditions like hidradenitis suppurativa and psoriasis. Founded in 2021, it operates under the leadership of CEO Dr. Jorge Santos da Silva and employs around 130 people.

Bottom Line

This insider purchase by Phillips Andrew John adds an interesting dimension to MoonLake Immunotherapeutics' stock activity. The company, while not yet profitable, is making strides in the biotechnology field with its innovative treatments. Investors often watch insider transactions closely as they can hint at management's confidence in the company's future. However, it's crucial to remember that this insider activity is just one piece of the puzzle when assessing a stock's potential.